Genelux Inventory
Inventory of Genelux (GNLX) as of Oct 17, 2026.
Get this data via API
Financial Data API
Inventory
-USD
Last updated:
Inventory of Genelux is 2026 - USD. Inventory of Genelux was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genelux Stock analysis
What does Genelux do? Genelux Corp, trading under the ticker GNLX, is a biotechnology company based in Westlake Village, California, operating within the Health Care sector. The company has 25 employees and completed its initial public offering on January 26, 2023. Genelux focuses on developing oncolytic viral immunotherapies for solid tumor cancers. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus (VACV), a stable DNA virus with significant engineering potential. The company is currently advancing Olvi-Vec through Phase II clinical trials for platinum-resistant or refractory ovarian cancer (PRROC). Additionally, Genelux is developing a platform called Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT), which aims to enhance cancer neoantigen-specific T cell activity within tumors. The company also has an animal health product candidate, V-VET1, a genetically characterized, veterinary-grade oncolytic vaccinia virus that is a naturally attenuated isolate. Genelux's website is https://genelux.com/ and it is registered with the ISIN US36870H1032. The company's operations and product development are centered on innovative viral-based therapies for both human and animal health applications. Genelux is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Genelux stock
On Eulerpool you can find the complete historical development of Inventory Genelux since 2006 – with annual values, charts, and detailed analysis.
Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.
Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Genelux historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — Genelux
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Genelux
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth